PulseAugur
EN
LIVE 19:05:03
中文(ZH) 长春高新：子公司GenSci144片境内生产药品注册临床试验申请获批

GenSci144 drug for chronic kidney disease gains Chinese clinical trial approval

By PulseAugur Editorial · [1 sources] ·

GenSci144, an oral small molecule inhibitor developed by Jinsai Pharmaceutical, has received approval for its clinical trial application in China. This drug targets the neutral amino acid transporter SLC6A19 and is intended for the treatment of chronic kidney disease (CKD). The approval marks a significant step for Jinsai Pharmaceutical's independent research and development efforts in the pharmaceutical sector. AI

IMPACT This drug development represents a step forward in pharmaceutical research, potentially offering new treatment options for chronic kidney disease.

RANK_REASON Clinical trial approval for a new drug. [lever_c_demoted from research: ic=1 ai=0.4]

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

GenSci144 drug for chronic kidney disease gains Chinese clinical trial approval

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Tool
Clinical trial approval for a new drug. [lever_c_demoted from research: ic=1 ai=0.4]
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
product, other
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
Standard
On-topic for AI-industry coverage; kept in the public index.
Story freshness
45 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    Changchun High-Tech: Subsidiary GenSci's application for clinical trial approval of domestically produced drugs has been approved

    36氪获悉，长春高新公告，近日，公司子公司金赛药业收到国家药监局核准签发的《药物临床试验批准通知书》，金赛药业GenSci144片境内生产药品注册临床试验申请获得批准。GenSci144片是金赛药业自主研发的一款靶向中性氨基酸转运蛋白SLC6A19的口服小分子抑制剂，注册分类为化药1类，拟用于慢性肾脏病（CKD）的治疗。

RELATED ENTITIES

RELATED TOPICS